DRE, a supplier of medical and operating room equipments, has received the US Food and Drug Administration (FDA ) approval for its touchscreen patient monitor Waveline Touch.

The DRE Waveline Touch, for use in in hospitals, surgery centers and medical practices, displays up to eight waveforms on a vivid 12.1 color display.

It provides multi-lead ECG monitoring, ST segment monitoring and up to 72 hours of trend data analysis.

DRE offers the Waveline Touch in configurations that measure ECG, respiration, SPO2, NIBP and temperature, and with optional dual invasive blood pressure and EtCO2 monitoring.

The DRE Waveline Touch integrates with the DRE Envoy TS telemetry system.

By interfacing the Waveline Touch with the Envoy TS, hospitals and surgery centers can track extended vital signs for multiple patients from the central monitoring station.

DRE Waveline Touch additional features include NIBP list display , built-in thermal recorder, networkable with a central monitoring system via a wireless or wired network.

It also includes features like 48 hours trend data analysis, compact design convenient for mobile monitoring, multi-lingual settings, available with battery and built-in recorder.

DRE’s monitoring line also includes Waveline EZ, a lightweight, portable monitor, Waveline Pro, a network-ready multi-parameter anesthesia gas monitor that can display eight vibrant waveforms on a 15 flat panel display, Waveline Echo, measure, SPO2 and quick temp.